ALEXION PHARMACEUTICALS, INC.

ALEXION PHARMACEUTICALS, INC. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
1992-01-01
Employees
3.8K
Market Cap
-
Website
http://www.alexion.com

Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects

First Posted Date
2021-06-09
Last Posted Date
2022-02-11
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
97
Registration Number
NCT04920370
Locations
🇬🇧

Clinical Study Site, London, United Kingdom

Study of Radiolabeled Danicopan in Healthy Male Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-05-17
Last Posted Date
2021-05-17
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
8
Registration Number
NCT04889391
Locations
🇳🇿

Clinical Trial Site, Auckland, New Zealand

Study of Multiple Doses of Danicopan in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-05-17
Last Posted Date
2021-05-17
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
45
Registration Number
NCT04889690
Locations
🇳🇿

Clinical Trial Site, Auckland, New Zealand

Study of a Single Dose of Danicopan in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-05-17
Last Posted Date
2021-05-17
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
44
Registration Number
NCT04889677
Locations
🇳🇿

Clinical Trial Site, Auckland, New Zealand

COVID-19 Soliris Expanded Access Protocol

Conditions
First Posted Date
2021-03-17
Last Posted Date
2021-10-04
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Registration Number
NCT04802083

A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome

Phase 3
Completed
Conditions
Interventions
First Posted Date
2021-02-12
Last Posted Date
2024-02-09
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
57
Registration Number
NCT04752566
Locations
🇯🇵

Clinical Trial Site, Yokohama, Japan

Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

First Posted Date
2021-02-08
Last Posted Date
2024-10-01
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
16
Registration Number
NCT04743804
Locations
🇬🇧

Research Site, Stevenage, United Kingdom

A Study of ALXN1830 in Healthy Adult Participants

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2021-01-29
Last Posted Date
2023-01-31
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
48
Registration Number
NCT04730804
Locations
🇳🇿

Research Site, Grafton, New Zealand

🇳🇿

Clinical Trial Site, Auckland, New Zealand

A Drug Interaction Study of ACH-0145228

First Posted Date
2021-01-14
Last Posted Date
2021-01-14
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
38
Registration Number
NCT04709081
Locations
🇺🇸

Clinical Study Site, Tempe, Arizona, United States

© Copyright 2024. All Rights Reserved by MedPath